Phase 4 Fluticasone Furoate Nasal Spray (VERAMYST) Long Term Pediatric Growth Study.
Status:
Completed
Trial end date:
2011-03-17
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to characterize, as accurately as possible, the
estimation of the difference in pre-pubescent growth velocities between subjects treated
continuously for one year with FFNS 110mcg QD, the highest dose approved for pediatric use in
the US, and placebo nasal spray as determined by stadiometry.